Gustave Roussy shared on LinkedIn:
“5 questions for Dr François-Xavier Danlos on therapeutic cancer vaccines.
Therapeutic vaccines against cancer are making significant advances in their clinical development.
The ESMO – European Society for Medical Oncology Congress, which starts on 23 October, will provide an opportunity to obtain new data on a therapeutic vaccine against melanoma.
But there are important differences between vaccines traditionally used to prevent the onset of disease and therapeutic vaccines against cancer.
- This summer, a therapeutic vaccine against melanoma has had a strong impact. Why?
- How can this vaccine ‘educate’ our immune system?
- In oncology, is it always necessary to create a new vaccine for each patient?
- Are vaccine technologies other than messenger RNA being studied?
- Vaccines to prevent cancer, is this science fiction?
Dr. François-Xavier Danlos, a medical oncologist in the Therapeutic Innovation and Early Trials Department at Gustave Roussy, a specialist in the development of immunotherapies, takes stock of the situation.”
Read the news: 5 questions for Dr François-Xavier Danlos on therapeutic cancer vaccines.
Jean-Pierre Armand, Consultant senior at Chinese Academy of Sciences, added:
“The goal remains the same: to train lymphocytes to identify cancer cells more effectively and eliminate them.
The Tedopi vaccine, evaluated at Gustave Roussy in clinical trials focused on lung and ovarian cancers, is based on this technology.”
Other articles about cancer vaccines on OncoDaily.